Clinical trial
A Phase Ib/II Study of AK138D1 as Monotherapy and in Combination With Ivonescimab in Patients With Advanced Breast Cancer
NCT07560124 is registered in ClinicalTrials.gov with Akeso as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ib/II Study of AK138D1 as Monotherapy and in Combination With Ivonescimab in Patients With Advanced Breast Cancer
- Lead sponsor
- Akeso
- Phase
- Phase 1/2
- Overall status
- Not yet recruiting
- Start date
- June 6, 2026
- Completion date
- September 14, 2030
- Enrollment
- 286 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer